Loading patent…
AssigneeUniversity of Louisville Research Foundation, Inc.
InventorsJohn W. Eaton, Kavitha Yaddanapudi, Chi Li
Estimating the term…
Provided are compositions, optionally pharmaceutical compositions, that include a plurality of exosomes generated from stem cells, optionally ESCs and/or iPSCs, that have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a human GM-CSF polypeptide. Also provided are methods for employing the presently disclosed compositions for preventing and/or inhibiting tumor growth in subjects in need thereof, for preventing and/or inhibiting metastases in subject in need thereof, for inducing anti-tumor immune responses in subjects, and uses of the presently disclosed compositions for prevention and/or treatment of tumors and/or cancers and for the preparation of medicaments for treatment of tumors and/or cancers.
A composition comprising a plurality of exosomes generated from stem cells, optionally embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), or a combination thereof, which have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a mammalian GM-CSF polypeptide.
2-3. (canceled)
(canceled)
A method for preventing and/or inhibiting tumor growth in a subject, the method comprising administering to the subject one or more doses of a composition comprising a plurality of exosomes generated from stem cells, optionally embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), or a combination thereof, which have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a mammalian GM-CSF polypeptide, in an amount and via a route of administration sufficient to prevent and/or inhibit tumor growth in the subject.
14-15. (canceled)
17-22. (canceled)
A method for inducing an anti-tumor immune response in a subject, the method comprising administering to the subject a composition comprising one or more pharmaceutically acceptable carriers and/or excipients and a plurality of exosomes generated from stem cells that have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide.
Dependencies are inferred from the claim text.